Kakati R, Whitman A, Haase S, Szenasi A, Thai C, Brunk E
bioRxiv. 2025; .
PMID: 39975402
PMC: 11838206.
DOI: 10.1101/2024.12.19.629395.
Kindt C, Ehmsen S, Traynor S, Policastro B, Nissen N, Jakobsen M
Front Oncol. 2025; 14:1497093.
PMID: 39931212
PMC: 11808005.
DOI: 10.3389/fonc.2024.1497093.
Beresford M, Casbard A, Hudson Z, Carucci M, Ingarfield K, Gee J
BJC Rep. 2024; 1(1):13.
PMID: 39516358
PMC: 11523984.
DOI: 10.1038/s44276-023-00016-8.
Di Grazia G, Conti C, Nucera S, Motta G, Martorana F, Stella S
Front Oncol. 2024; 14:1427228.
PMID: 39211557
PMC: 11358597.
DOI: 10.3389/fonc.2024.1427228.
Jagust P, Powell A, Ola M, Watson L, de Pablos-Aragoneses A, Garcia-Gomez P
J Natl Cancer Inst. 2024; 116(10):1632-1644.
PMID: 38852945
PMC: 11461165.
DOI: 10.1093/jnci/djae091.
Unveiling the Neural Environment in Cancer: Exploring the Role of Neural Circuit Players and Potential Therapeutic Strategies.
Nguyen T, Ngoc D, Choi J, Lee C
Cells. 2023; 12(15).
PMID: 37566075
PMC: 10417274.
DOI: 10.3390/cells12151996.
RET signaling in breast cancer therapeutic resistance and metastasis.
Pecar G, Liu S, Hooda J, Atkinson J, Oesterreich S, Lee A
Breast Cancer Res. 2023; 25(1):26.
PMID: 36918928
PMC: 10015789.
DOI: 10.1186/s13058-023-01622-7.
A network map of GDNF/RET signaling pathway in physiological and pathological conditions.
Mol P, Devasahayam Arokia Balaya R, Dagamajalu S, Babu S, Chandrasekaran P, Raghavan R
J Cell Commun Signal. 2023; 17(3):1089-1095.
PMID: 36715855
PMC: 10409931.
DOI: 10.1007/s12079-023-00726-1.
JMJD6 orchestrates a transcriptional program in favor of endocrine resistance in ER+ breast cancer cells.
Das P, Gupta A, Desai K
Front Endocrinol (Lausanne). 2022; 13:1028616.
PMID: 36419768
PMC: 9678079.
DOI: 10.3389/fendo.2022.1028616.
Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.
Zheng Z, Xia L, Hu G, Liu J, Hu Y, Chen Y
Nucleic Acids Res. 2022; 50(18):10230-10248.
PMID: 36124682
PMC: 9561272.
DOI: 10.1093/nar/gkac778.
RET signaling pathway and RET inhibitors in human cancer.
Regua A, Najjar M, Lo H
Front Oncol. 2022; 12:932353.
PMID: 35957881
PMC: 9359433.
DOI: 10.3389/fonc.2022.932353.
MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET.
Srivastava A, Tommasi C, Sessions D, Mah A, Bencomo T, Garcia J
Cancer Res. 2022; 82(17):3143-3157.
PMID: 35705526
PMC: 9444977.
DOI: 10.1158/0008-5472.CAN-22-0047.
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F, Neha K, Chauhan G
Arch Pharm Res. 2022; 45(5):309-327.
PMID: 35598228
DOI: 10.1007/s12272-022-01385-3.
The Emerging Portrait of Glial Cell Line-derived Neurotrophic Factor Family Receptor Alpha (GFRα) in Cancers.
Li Q, Cao Z, Zhao S
Int J Med Sci. 2022; 19(4):659-668.
PMID: 35582425
PMC: 9108399.
DOI: 10.7150/ijms.64133.
RET in breast cancer: pathogenic implications and mechanisms of drug resistance.
Lo Nigro C, Rusmini M, Ceccherini I
Cancer Drug Resist. 2022; 2(4):1136-1152.
PMID: 35582269
PMC: 9019211.
DOI: 10.20517/cdr.2019.66.
Aberrant RET expression affects normal mammary gland post-lactation transition, enhancing cancer potential.
Vallone S, Garcia Sola M, Schere-Levy C, Meiss R, Hermida G, Chodosh L
Dis Model Mech. 2022; 15(3).
PMID: 35044452
PMC: 8990024.
DOI: 10.1242/dmm.049286.
Comprehensive immunohistochemical analysis of RET, BCAR1, and BCAR3 expression in patients with Luminal A and B breast cancer subtypes.
Pavanelli A, Mangone F, Yoganathan P, Bessa S, Nonogaki S, de Toledo Osorio C
Breast Cancer Res Treat. 2022; 192(1):43-52.
PMID: 35031902
DOI: 10.1007/s10549-021-06452-9.
[Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].
Zheng Y, Jiang W, Chen D, Li Y, Dai L, Huang L
Zhongguo Fei Ai Za Zhi. 2021; 24(8):591-597.
PMID: 34120433
PMC: 8387645.
DOI: 10.3779/j.issn.1009-3419.2021.102.22.
Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.
Fancelli S, Caliman E, Mazzoni F, Brugia M, Castiglione F, Voltolini L
Cancers (Basel). 2021; 13(5).
PMID: 33806299
PMC: 7961559.
DOI: 10.3390/cancers13051091.
Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity.
Hou Y, Liang H, Yu X, Liu Z, Cao X, Rao E
Sci Transl Med. 2021; 13(582).
PMID: 33627484
PMC: 8710940.
DOI: 10.1126/scitranslmed.abb0130.